Competition Council Examines Medicine Distribution
Morocco's Competition Council is examining medicine distribution, with issues linked to prices, margins, generics, quality and competitive practices.
Meeting Context
Morocco's Competition Council will hold a meeting on March 6, 2025 with pharmaceutical industry stakeholders to examine competition in medicine distribution. This initiative, as part of a self-initiated review under Law No. 20-13 and Law No. 104-12, aims to guarantee a fair market for Moroccan consumers.
Main Themes
The discussions will focus in particular on:
- Quality and safety: Ensuring that distributed medicines meet standards in order to protect public health.
- Pricing and margins: Verifying that prices are fair and competitive, without practices such as price-fixing.
- Promotion of generics: Encouraging the use of generics to reduce costs and improve access to care.
Roles of Professional Organizations
Each professional organization, such as manufacturers' and distributors' associations, will be asked to assess its scope of intervention. Manufacturers are responsible for production and imports, distributors manage logistics, and retail pharmacies sell directly to consumers. The Council could examine whether their actions, such as exclusive agreements or pricing practices, affect competition.
Potential Implications
The results of this meeting could influence public-health policies, particularly by strengthening regulations to combat anti-competitive practices, adjusting prices to improve affordability, and encouraging generics to support AMO. The recommendations could also have repercussions for pharmaceutical exports, where Morocco aims to become a hub for Africa.
Comparative Overview: Issues and Challenges
Here is a summary of the issues and challenges associated with the themes discussed:
- Quality and Safety: issues linked to protecting public health and fighting counterfeit medicines; challenges related to enforcing regulations and barriers to entry.
- Pricing: issues of affordability and fair margins; challenges related to collusive practices and price-fixing.
- Promotion of Generics: issues of cost reduction and broader access; challenges related to patient mistrust and competitive barriers.
Pharmaceutical Distribution Sector in Morocco
Morocco's pharmaceutical sector is robust, ranking second in Africa by volume, with local production covering around 65% of national needs (Pharmaceutical - Morocco Now). Generics dominate, representing 80-90% of the public market and 25% of the private market, according to a Business Monitor International study (Morocco Pharmaceutical Market 2024-2030). Distribution involves several stakeholders, including manufacturers (local and multinational), distributors, retail pharmacies and regulatory bodies such as the Ministry of Health.
This sector is highly regulated, with standards aligned with international benchmarks such as the U.S. FDA and the European Directorate for the Quality of Medicines and Healthcare (Pharmaceutical - Morocco Now). However, challenges remain, including illegal medicine trafficking, which compromises quality and safety, and pricing concerns, with recent reforms aimed at reducing margins and VAT on certain medicines (Editorial: Medicines pricing, access and safety in Morocco).
Conclusion
In summary, the March 6, 2025 meeting is an important step in assessing and improving competition in pharmaceutical distribution in Morocco. Discussions on quality, prices and generics could lead to recommendations that strengthen the sector, benefit consumers and support public-health objectives.